Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - hydrochlorothiazide; irbesartan - tablet, film coated - 12.50 mg - hydrochlorothiazide 12.50 mg; irbesartan 300.00 mg

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

sanofi winthrop industrie - dupilumab - dupilumab....300 mg

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

sanofi winthrop industrie - enoxaparina sÓdica - enoxaparina sÓdica....20 mg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

sanofi winthrop industrie, france - lansoprazole - capsule - 30 mg

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

sanofi winthrop industrie - alfuzosina hidrocloruro - alfuzosina hidrocloruro....10.00 mg

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

sanofi winthrop industrie - zolpidem tartrato - zolpidem tartrato....12,50 mg

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

sanofi winthrop industrie - dupilumab - dupilumab....200 mg/1,14 ml

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - glibenclamide - tablets - 5 milligram

European Union - English - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agents for dermatitis, excluding corticosteroids - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy.asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5.1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment.children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment.chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy.eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

European Union - English - EMA (European Medicines Agency)

sanofi winthrop industrie - dronedarone - atrial fibrillation - cardiac therapy - multaq is indicated for the maintenance of sinus rhythm after successful cardioversion in adult clinically stable patients with paroxysmal or persistent atrial fibrillation (af). due to its safety profile, multaq should only be prescribed after alternative treatment options have been considered.multaq should not be given to patients with left ventricular systolic dysfunction or to patients with current or previous episodes of heart failure.